Drug Profile


Alternative Names: Signifor; Signifor LAR; SOM-230; SOM230C; SOM230LAR

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Antineoplastics; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin-releasing factor antagonists; Growth hormone releasing factor antagonists; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary ACTH hypersecretion; Neuroendocrine tumours
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pituitary ACTH hypersecretion
  • Registered Acromegaly
  • Phase III Pancreatic disorders
  • Phase II Cluster headache; Gastrointestinal disorders; Gigantism; Hepatocellular carcinoma; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
  • Phase I Gastrointestinal cancer; Malignant melanoma; Merkel cell carcinoma; Pancreatic cancer
  • Preclinical Radiation injuries
  • Discontinued Carcinoid tumour

Most Recent Events

  • 26 Jan 2017 Novartis completes a phase III trial for Pituitary ACTH Hypersecretion in USA, Brazil, Czech Republic, Germany, Greece, Lebanon, Romania, Russia, Spain, South Korea, the Netherlands, Thailand (NCT01582061; EudraCT2010-024165-44)
  • 07 Oct 2016 Adverse events data from a phase I trial in Malignant melanoma or Merkel cell carcinoma presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 07 Oct 2016 Efficacy and adverse event data from a phase II trial in Neuroendocrine carcinoma presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top